Anti-Cancer Acitivity of Etodolac and Its Derivatives on Prostate and Colorectal Cancer Cell Lines

Creative Commons License

Koçyiğit Sevinç S., Orun O., Mega Tiber P., Süzgün P., Küçükgüzel Ş. G.

PROCEEDINGS (MDPI), cilt.2, ss.1573, 2018 (Hakemli Dergi)

  • Yayın Türü: Makale / Özet
  • Cilt numarası: 2
  • Basım Tarihi: 2018
  • Doi Numarası: 10.3390/proceedings2251573
  • Dergi Adı: PROCEEDINGS (MDPI)
  • Derginin Tarandığı İndeksler: Directory of Open Access Journals
  • Sayfa Sayıları: ss.1573
  • Marmara Üniversitesi Adresli: Evet

Özet

Abstract: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used as anti-inflammatory

and analgesic agents. This family of drugs suppresses prostaglandin synthesis through inhibition

of cyclooxygenase (COX) enzymes. Recent studies showed that anti-carcinogenic effects of these

drugs are especially mediated by COX-2 enzyme. Etodolac is a COX-2 inhibitor and though not

perfectly selective, it exhibits “preferential selectivity” for COX-2. In this study, the anti-proliferative

and apoptotic effects of etodolac and its hydrazone or triazole derivatives (SGK 206 and SGK 242,

respectively), were investigated on prostate cancer cell line PC-3 and human colorectal carcinoma

cell line HT-29. Our data showed that SGK 206 and SGK 242 were more effective in the inhibition of

proliferation and induction of apoptosis compared to etodolac in both cell lines.